22NW, LP holds a concentrated book of 14 reported positions worth $104.7M as of Q2 2026 (disclosed Aug 14, 2026, a ~45-day 13F lag). This quarter they opened Turtle Beach Corp and trimmed Mineralys Therapeutics Inc. Their largest long position is Insperity Inc at 19% of the reported non-option book. Cloning the disclosed picks since 2017 would be +330% (+16.5%/yr). That is a simulation of the disclosed long book, not audited returns.
Following at the filing date actually beat the quarter-end book by 8.5 points over this window.
Growth of $10,000 cloning 22NW, LP's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~45 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
+1 sector below the cut, under 0.5% together
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices (an exit at the prior quarter-end), no cost basis
Other tracked managers holding the same core names as 22NW, LP
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| Prosight Management, LP | 2 / 14 | $68.7M |
| Sphera Funds Management LTD. | 2 / 14 | $44.4M |
| Act Capital Management, LLC | 3 / 14 | $7.8M |
| BVF Inc | 2 / 14 | $191.7M |
| Towle & Co | 2 / 14 | $14.0M |
| Catalio Capital Management, LP | 2 / 14 | $24.2M |
| DAFNA Capital Management LLC | 2 / 14 | $23.4M |
| Ishara Investments LP | 2 / 14 | $4.6M |
Ranked by the share of each fund's own book sitting in the names it shares with 22NW, LP: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each position's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Insperity Inc COM | $20.4M | 493.0K | 19.5% | —Held | |
| 2 | Nektar Therapeutics COM NEW | $19.6M | 281.1K | 18.7% | —Held | |
| 3 | Stoneridge Inc COM | $18.1M | 2.47M | 17.3% | —Held | |
| 4 | Fox Factory Hldg Corp COM | $11.5M | 678.2K | 11.0% | —Held | |
| 5 | Core Molding Technologies In COM | $6.5M | 273.5K | 6.2% | ▲+23% Added · +51K sh | |
| 6 | Regenxbio Inc COM | $5.9M | 492.8K | 5.6% | —Held | |
| 7 | Culp Inc COM | $5.8M | 1.86M | 5.5% | —Held | |
| 8 | Rezolute Inc COM NEW | $4.3M | 820.7K | 4.1% | —Held | |
| 9 | Unifi Inc COM NEW | $4.0M | 852.5K | 3.9% | —Held | |
| 10 | Mineralys Therapeutics Inc COM | $3.1M | 113.8K | 2.9% | ▼−74% Reduced · −330K sh | |
| 11 | Team Inc COM NEW | $2.9M | 170.2K | 2.8% | —Held | |
| 12 | Eledon Pharmaceuticals Inc COM | $2.5M | 636.4K | 2.4% | —Held | |
| 13 | Turtle Beach Corp COM NEW | $180K | 14.4K | 0.2% | ▲New New position | |
| 14 | Lifecore Biomedical Inc COM | $6K | 1.3K | <0.1% | —Held |
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1694297/holdings"
Use Arkolith to show 22NW, LP's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Reported 13F total per quarter. Raw filing totals can include option notional.
| Quarter | As of | Filed | Lag | Positions | Value | Form |
|---|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Aug 14, 2026 | 45d | 14 | $104.7M | 13F-HR |
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 45d | 16 | $145.9M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 13, 2026 | 44d | 20 | $237.6M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 45d | 21 | $212.3M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 45d | 21 | $158.8M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 14, 2025 | 44d | 20 | $149.1M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 45d | 16 | $158.5M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 45d | 13 | $119.3M | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 45d | 13 | $117.2M | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 45d | 13 | $116.1M | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 45d | 14 | $153.5M | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 45d | 14 | $140.3M | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 45d | 14 | $160.1M | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 45d | 17 | $162.7M | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 10, 2023 | 41d | 19 | $185.2M | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 45d | 20 | $176.8M | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 12, 2022 | 43d | 20 | $188.4M | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 13, 2022 | 43d | 25 | $275.4M | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 45d | 25 | $323.4M | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 12, 2021 | 43d | 28 | $335.7M | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Aug 16, 2021 | 47d | 34 | $372.1M | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 14, 2021 | 44d | 36 | $324.6M | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 12, 2021 | 43d | 35 | $279.3M | 13F-HR |
| Q3 2020 | Sep 30, 2020 | Nov 13, 2020 | 44d | 39 | $197.2M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. Book totals and portfolio weights cover reported non-option positions, which can include notes and warrants. Disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.